Navigation Links
CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
Date:4/14/2017

ROCKVILLE, Md., April 14, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, reported today that along with the investigators a  decision has been reached to stop further patient enrollment in its Phase 2, open-label study of ENMD-2076 in previously treated locally advanced or metastatic triple-negative breast cancer (TNBC) conducted at the University of Colorado, Denver and the Indiana University Melvin and Bren Simon Cancer Center.  The study was a 2 stage design which targeted an accrual of 35 patients. The patient number was expanded to take into consideration those patients which may not be evaluable for efficacy analysis as per the protocol. In this uncommon tumor type and challenging setting to recruit, a total of 41 patients have been enrolled which has been determined to be sufficient to assess the potential efficacy of ENMD-2076 in this patient population and for our ongoing biomarker analysis.  The Company continues to collect and evaluate data in those patients enrolled in the study, and the biomarker program which evaluates potential markers that could be predictive of a response to ENMD-2076 is ongoing.  In addition, the ongoing Phase 2a study in China in patients with TNBC continues to accrue patients in the dose escalation phase, the primary objective of which is to determine the recommended Phase 2 dose in Chinese study subjects.  This dose escalation phase is expected to reach the full accrual target in Q3 2017.

Dr. Alex Zukiwski, CASI's Chief Medical Officer, commented, "We continue to evaluate the maturing data including the biomarker analysis to determine the potential future development path in patients with TNBC. Identifying markers predictive of response to ENMD-2076 in patients with TNBC would be helpful to future development as a single agent, as well as consideration of any additional trials where ENMD-2076 could be combined with approved agents to increase clinical benefit."

Along with the investigators, the Company plans to present the study results at the next available opportunity.

About CASI Pharmaceuticals, Inc.

CASI is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. CASI's product pipeline features (1) our lead proprietary drug candidate, ENMD-2076, in multiple Phase 2 clinical trials, (2) MARQIBO®, ZEVALIN® and EVOMELA®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory process for market approval in China, and (3) proprietary early-stage candidates in preclinical development.  CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in the Company's filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.  Actual results could differ materially from those currently anticipated due to a number of factors, including: that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of executing our business strategy in China; our inability to predict when or if our product candidates will be approved for marketing by CFDA authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

MARQIBO®, EVOMELA® and ZEVALIN® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.

COMPANY CONTACT:

CASI Pharmaceuticals, Inc.

240.864.2643

ir@casipharmaceuticals.com

 

INVESTOR CONTACT:

Torrey Hills Capital

Jim Macdonald

858.456.7300

 jm@sdthc.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-reports-on-enrollment-status-of-enmd-2076-phase-2-study-in-triple-negative-breast-cancer-300439623.html


'/>"/>
SOURCE CASI Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
2. Foresee Pharmaceuticals Announces Key Executive Appointments
3. DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
4. Hi-Tech Pharmaceuticals Expands With Opening of West Coast Distribution Center
5. Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
6. AcelRx Pharmaceuticals Presenting Comprehensive DSUVIA Clinical Trial Results at ASRAs Annual Regional Anesthesiology and Acute Pain Medicine Meeting
7. Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation
8. Sheffield Pharmaceuticals Introduces Dr. Sheffields Premium Natural Toothpaste Line
9. Braeburn Pharmaceuticals Applauds Repeal of HB2
10. Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes
11. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the development of ... R&D and Head of Virology Kristin Bedard has been invited ... and Beyond meeting sponsored by Life Science Washington.  This ... AM PDT at the Agora Conference Center in ... be joined by other leaders in infectious disease research and ...
(Date:6/9/2017)... 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders or ... manufacture, sale and distribution of the AeroForm® Tissue Expander ... its commercial roll-out in the United States ... one hundred (100) medical institutions and health systems, located ... needle-free alternative for women who choose reconstructive surgery following ...
(Date:6/8/2017)... , June 8, 2017   Responding to Heath ... and the death of singer Chris Cornell in ... Rights International offers a free online psychiatric ... consumers and families about psychotropic drug risks. ... who died from an accidental overdose, has called for tighter ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the ... are currently accepting new patients at their practice for these custom clear aligners. These ... is why they offer the latest in modern dental techniques to ensure that all ...
(Date:6/20/2017)... Ariz. (PRWEB) , ... June 20, 2017 , ... ... Natural Brands®, makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted ... Sun Corridor Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other ...
(Date:6/20/2017)... ... ... John D'Eri, CEO of Rising Tide Car Wash , will accept ... the Autism Society of America 's 49th annual conference to be held this ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively on ...
(Date:6/20/2017)... ... ... The law firm of Momkus McCluskey Roberts LLC congratulates attorney ... Bar Association’s Board of Directors. Cassioppi officially took on the leadership role during the ... Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as the DCBA’s ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... new operating rooms this month. These additions will expand the capabilities of the ... facilities. One operating room will be solely dedicated to pediatric operations, while the ...
Breaking Medicine News(10 mins):